Transition Therapeutics (Transition Therapeutics) Net Issuance of Debt : $0.00 Mil (TTM As of Mar. 2016)

View and export this data going back to 2007. Start your Free Trial

What is Transition Therapeutics Net Issuance of Debt?

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. Transition Therapeutics's net issuance of debt for the three months ended in Mar. 2016 was $0.00 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Mar. 2016 was $0.00 Mil.

Transition Therapeutics Net Issuance of Debt Historical Data

The historical data trend for Transition Therapeutics's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Transition Therapeutics Net Issuance of Debt Chart

Transition Therapeutics Annual Data

Trend

Jun06

Jun07

Jun08

Jun09

Jun10

Jun11

Jun12

Jun13

Jun14

Jun15

Net Issuance of Debt

Get a 7-Day Free Trial

Transition Therapeutics Quarterly Data
	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16
Net Issuance of Debt	Get a 7-Day Free Trial															-	-	-	-	-

Transition Therapeutics Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Transition Therapeutics Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Transition Therapeutics's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Transition Therapeutics (Transition Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transition Therapeutics Inc (NAS:TTHI) » Definitions » Net Issuance of Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.transitiontherapeutics.com

Transition Therapeutics Inc was incorporated on July 6, 1998 as 'Transition Therapeutics and Diagnostics Inc.' The Corporation filed articles of amendment on October 12, 2000 and on October 19, 2000 to create a class of non-voting shares (the 'Class B Shares') and to amend certain attributes of its Common Shares. On November 2, 2000, the Corporation filed articles of amendment to delete its private company restrictions. On December 14, 2000, the Corporation filed articles of amendment to change its name to 'Transition Therapeutics Inc.' The Company's technologies are focused on the treatment of Alzheimer's disease and diabetes. The Corporation operates in one business segment; that is the research and development of therapeutic agents. Its technologies in development include ELND005 (AZD-103) for the treatment of Alzheimer's disease. On April 30, 2013, the Company announced the results of a five-week proof of concept clinical study of TT401 in type 2 diabetic and obese non-diabetic subjects. In the study, TT401, a once weekly administered peptide, demonstrated improvements in glycemic control and reductions in body weight.

Executives

Jack W Schuler	10 percent owner	100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Family Foundation Schuler	10 percent owner	100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045

Transition Therapeutics (Transition Therapeutics) Headlines

From GuruFocus

Hardest Hit Companies of the Day: Transition Therapeutics Inc., Sunesis Pharmaceuticals Inc., GenCorp Inc., Cyclacel Pharmaceuticals Inc., FactSet Research Systems Inc.

By guruek guruek • 12-15-2009